Jiangbo Pharmaceuticals, Inc. (Jiangbo), formerly Genesis Pharmaceuticals Enterprises, Inc., is a holding company. The Company operates, controls and owns the pharmaceutical business of Laiyang Jiangbo Pharmaceutical Co., Ltd. (Laiyang Jiangbo). Laiyang Jiangbo researches, develops, manufactures, markets and sells pharmaceutical products and health supplements in the PRC. Laiyang Jiangbo produces tablets, capsules, granules, syrup and electuary for both Western medical drugs and Chinese herbal-based medical drugs. Approximately 35% of its products are Chinese herbal-based drugs and 65% are Western medical drugs. In February 2009, the Company acquired Shandong Hongrui Pharmaceutical Factory (Shandong Hongrui).

Merial Limited company makes a variety of drugs and vaccines that treat and prevent disease in pets, livestock, and wildlife. Used by veterinarians, farmers, and pet owners in some 150 countries, Merial company's products include Ivomec, an anti-parasitic for livestock; Frontline flea and tick treatments for cats and dogs; heartworm prevention drug Heartgard; and rabies vaccine Raboral. Merial focuses its R&D on combating parasites, viral and bacterial invaders, and pain, as well as treating chronic conditions of household pets. Merial company is owned by Sanofi-Aventis.

Premier Research Group, Ltd. was founded in 2002 and is based in Wokingham, United Kingdom. Premier Research Group, Ltd., a contract research organization, provides clinical trial management and information services to the pharmaceutical and biotechnology industries in Europe, Asia, Africa, Australia, Latin America, and North America. The company focuses its research and development program on enhancing software systems used to support its clinical trials management and information services. Its services include dedicated clinical sites, medical and safety management, medical writing, data management, biostatistics, interactive voice response systems, regulatory affairs, and quality assurance. The company conducts its clinical research in the areas of infectious diseases, oncology, pediatrics, analgesia, and CNS. The company was formerly known as CRC Development Limited and changed its name to Premier Research Group, Ltd. in November, 2004.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

The National Institutes of Health (NIH), through its own research and the distribution of grants, seeks to understand disease inside and out. Part of the US Department of Health and Human Services, the NIH is the government's main medical research entity. It comprises 27 institutes and centers covering every medical discipline, from general medical sciences to alternative therapies. The organization has nearly 6,000 scientists of its own and gives out some 50,000 grants to researchers at more than 3,000 universities, hospitals, and research labs in all 50 states. Among its vast array of projects, NIH has supported efforts to develop an AIDS vaccine, map human genetic variation, and study avian flu.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company’s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

MedImmune works to boost the immune systems of babies and grown-ups. Its flagship biotech product, Synagis, prevents respiratory syncytial virus (RSV), a major cause of pneumonia and other respiratory disease in infants and children. Also on the market are FluMist, its nasal spray flu vaccine, and Ethyol, which treats side effects of chemotherapy and radiation. The company is working on dozens of investigational therapies -- including monoclonal antibodies, vaccines, and small molecule drugs -- in the areas of infectious diseases, cancer, and inflammatory conditions. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca.

GelStat Corporation engages in the development and marketing of over the counter and other nonprescription consumer health care products for pain and inflammation. It markets GelStat Migraine, a homeopathic drug, for the treatment of migraine and migraine-like headaches, as well as GelStat Arthritis, a sublingual dissolving tablet for the treatment of pain and associated symptoms of arthritis. The company is also developing other products that are in the final stages of development, which include GelStat Sinus for the remedy of nasal and/or sinus congestion, irritation, pressure, and sinus headache; and GelStat Sleep for promoting restful sleep. The company sells its products to regional and national retailers, wholesalers, specialty distributors, and catalog merchandisers in the United States directly and through sales brokers. GelStat Corporation is based in Bloomington, Minnesota.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.